Skip to main content

Advertisement

SpringerLink
Log in

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells

  • Preclinical Study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Resistance to trastuzumab is a major issue in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Several potential resistance mechanisms have been investigated, but the results are controversial and no conclusion has been reached. Erythropoietin receptor (EPOR) may function in cell growth, and expressed in various cancer cells. Because the downstream signaling pathways for EPOR and HER2 partially overlapped, we hypothesized that EPOR may play a role in the inhibition effect of trastuzumab and resistance to trastuzumab. Here, we detected the expression of EPOR mRNA and protein in HER2-positive breast cancer cell lines and tissues. EPOR expressed in SKBR3, MDA-MB-453, and UACC-812 cell lines, but not in BT474. Of the 55 HER2-positive cancer tissues, EPOR was positive in 42 samples and highly expressed (H-score ≥ 25) in 24 by immunohistochemistry. The difference between EPOR expression and Ki67 index was significant (P = 0.033), and EPOR expression also positively correlated with higher pathological stage (Spearman correlation coefficient = 0.359; P = 0.007). Exogenous EPO antagonized trastuzumab-induced inhibition of cell proliferation in HER2/EPOR dual-positive breast cancer cells. We then exposed SKBR3 cells to trastuzumab for 4 months to obtain trastuzumab-resistant SKBR3 cell line, which demonstrated higher phosphorylated EPOR level, higher EPO expression and more extracellular secretion than non-resistant parental SKBR3 cells. Downregulation EPOR expression using short hairpin RNA resensitized trastuzumab-resistant cells to this drug, and SKBR3 cells with EPOR downregulation demonstrated attenuated trastuzumab resistance after the same resistance induction. EPOR downregulation plus trastuzumab produced a synergetic action in the inhibition of cell proliferation and invasion in SKBR3 and MDA-MB-453 cell lines. Therefore, EPOR expression may be involved in tumor progression and proliferation in HER2-positive breast cancer. EPO/EPOR contributes to the mechanism of trastuzumab resistance in SKBR3 cell lines, and EPOR downregulation can reverse the resistance to trastuzumab and increase the inhibition effect of this drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684. doi:10.1056/NEJMoa052122

    Article  PubMed  CAS  Google Scholar 

  2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672. doi:10.1056/NEJMoa052306

    Article  PubMed  CAS  Google Scholar 

  3. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642–1649. doi:10.1200/JCO.2007.11.6699

    Article  PubMed  CAS  Google Scholar 

  4. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Article  PubMed  CAS  Google Scholar 

  5. Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51. doi:10.1056/NEJMra043186

    Article  PubMed  CAS  Google Scholar 

  6. Garrett JT, Arteaga CL (2011) Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 11:793–800

    Article  PubMed  CAS  Google Scholar 

  7. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127. doi:10.1016/j.ccr.2004.06.022

    Article  PubMed  CAS  Google Scholar 

  8. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402. doi:10.1016/j.ccr.2007.08.030

    Article  PubMed  CAS  Google Scholar 

  9. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118–11128. doi:10.1158/0008-5472.CAN-04-3841

    Article  PubMed  CAS  Google Scholar 

  10. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17:461–469. doi:10.1038/nm.2309

    Article  PubMed  Google Scholar 

  11. Khoury T, Kanehira K, Wang D, Ademuyiwa F, Mojica W, Cheney R, Morrison C, Conroy J, Nowak N, Liu S (2010) Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis. Mod Pathol 23:1364–1378. doi:10.1038/modpathol.2010.125

    Article  PubMed  CAS  Google Scholar 

  12. Jelkmann W (2007) Erythropoietin after a century of research: younger than ever. Eur J Haematol 78:183–205. doi:10.1111/j.1600-0609.2007.00818.x

    Article  PubMed  CAS  Google Scholar 

  13. Henry DH, Abels RI (1994) Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 21:21–28

    PubMed  CAS  Google Scholar 

  14. Lappin TR, Maxwell AP, Johnston PG (2002) EPO’s alter ego: erythropoietin has multiple actions. Stem Cells 20:485–492. doi:10.1634/stemcells.20-6-485

    Article  PubMed  CAS  Google Scholar 

  15. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12:332–339. doi:10.1158/1078-0432.CCR-05-1771

    Article  PubMed  CAS  Google Scholar 

  16. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260. doi:10.1016/S0140-6736(03)14567-9

    Article  PubMed  CAS  Google Scholar 

  17. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009) Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373:1532–1542. doi:10.1016/S0140-6736(09)60502-X

    Article  PubMed  CAS  Google Scholar 

  18. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z (2010) Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18:423–435. doi:10.1016/j.ccr.2010.10.025

    Article  PubMed  CAS  Google Scholar 

  19. Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X, Acs G (2009) RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol 174:1504–1514. doi:10.2353/ajpath.2009.080592

    Article  PubMed  CAS  Google Scholar 

  20. Pelekanou V, Kampa M, Kafousi M, Dambaki K, Darivianaki K, Vrekoussis T, Sanidas E, Tsiftsis DD, Stathopoulos EN, Castanas E (2007) Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev 16:2016–2023. doi:10.1158/1055-9965.EPI-06-1023

    Article  PubMed  CAS  Google Scholar 

  21. Doleschel D, Mundigl O, Wessner A, Gremse F, Bachmann J, Rodriguez A, Klingmuller U, Jarsch M, Kiessling F, Lederle W (2012) Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts. J Nucl Med 53:304–311. doi:10.2967/jnumed.111.091124

    Article  PubMed  CAS  Google Scholar 

  22. Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL, Xenocostas A (2011) Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res 17:6151–6162. doi:10.1158/1078-0432.CCR-10-3298

    Article  PubMed  CAS  Google Scholar 

  23. Bohlius J, Weingart O, Trelle S, Engert A (2006) Cancer-related anemia and recombinant human erythropoietin—an updated overview. Nat Clin Pract Oncol 3:152–164. doi:10.1038/ncponc0451

    Article  PubMed  CAS  Google Scholar 

  24. Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd (2012) Cancer- and chemotherapy-induced anemia. J Natl Compr Cancer Netw 10:628–653

    Google Scholar 

  25. Mohyeldin A, Dalgard CL, Lu H, McFate T, Tait AS, Patel VC, Wong K, Rushing E, Roy S, Acs G, Verma A (2007) Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg 106:338–350. doi:10.3171/jns.2007.106.2.338

    Article  PubMed  CAS  Google Scholar 

  26. Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TR (2010) Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 8:615–626. doi:10.1158/1541-7786.MCR-09-0264

    Article  PubMed  CAS  Google Scholar 

  27. Wu P, Zhang N, Wang X, Zhang C, Li T, Ning X, Gong K (2012) The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells. PLoS ONE 7:e45122. doi:10.1371/journal.pone.0045122

    Article  PubMed  CAS  Google Scholar 

  28. Mannello F, Fabbri L, Ciandrini E, Tonti GA (2008) Increased levels of erythropoietin in nipple aspirate fluid and in ductal cells from breast cancer patients. Cell Oncol 30:51–61

    PubMed  CAS  Google Scholar 

  29. Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W (2008) Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 122:1005–1011. doi:10.1002/ijc.23201

    Article  PubMed  CAS  Google Scholar 

  30. Larsson AM, Jirstrom K, Fredlund E, Nilsson S, Ryden L, Landberg G, Pahlman S (2009) Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res 15:5552–5559. doi:10.1158/1078-0432.CCR-08-3014

    Article  PubMed  CAS  Google Scholar 

  31. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561–3565

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that there are no conflicts of interest.

Author information

Authors and Affiliations

  1. Peking University First Hospital Breast Disease Centre, Xishiku Street 8#, Xicheng District, Beijing, China

    Chi Zhang, Xuening Duan, Ling Xu, Jingming Ye, Jianxin Zhao & Yinhua Liu

Authors
  1. Chi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuening Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ling Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jingming Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jianxin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yinhua Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xuening Duan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, C., Duan, X., Xu, L. et al. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat 136, 739–748 (2012). https://doi.org/10.1007/s10549-012-2316-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-2316-x

Keywords

Search

Navigation